SRNE

Sorrento Therapeutics, Inc.
CAPPED RATING

Sorrento Therapeutics Inc is a biotechnology company focused on the development of novel immunotherapies for oncology and autoimmune/inflammation diseases.

Sorrento Therapeutics, Inc. (SRNE) is rated C (2.2/5) on Deltasharpe Prism, scored against General sector peers. Its strongest pillar is Growth (B); its weakest is Momentum (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
B
Factor Score 3.4 / 5.0
Profitability
C+
Factor Score 2.6 / 5.0
Momentum
D
Factor Score 1.3 / 5.0
Revisions
D
Factor Score 1.5 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA N/A
Rev Growth YoY 44.3%
Gross Margin 52.5%
Price Return 3M -44.4%
Price Return 12M -64.3%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales N/A
ROE -68.8%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2022-09-30 C+ (2.5) B (3.4) C+ (2.6) D (1.3) D (1.5) C (2.2)
2022-06-30 C+ (2.5) D- (1.1) C+ (2.8) D (1.2) D (1.5) D+ (1.8)
2022-03-31 C+ (2.5) C+ (2.5) B- (3.1) D (1.3) D (1.5) C (2.2)
2021-12-31 C+ (2.5) C- (1.9) B- (3.1) D (1.3) D (1.5) C- (2.1)
2021-09-30 C+ (2.5) D+ (1.5) B- (3.1) D (1.3) D (1.5) C- (2.0)
Page 1 of 2